{"id":"NCT00648908","sponsor":"Acorda Therapeutics","briefTitle":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial","officialTitle":"Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2011-01","completion":"2011-04","firstPosted":"2008-04-01","resultsPosted":"2012-02-27","lastUpdate":"2012-02-27"},"enrollment":269,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Fampridine-SR","otherNames":["4-aminopyridine"]}],"arms":[],"summary":"The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who previously participated in Acorda Therapeutics Protocol MS-F203.","primaryOutcome":{"measure":"Summary of Treatment Emergent Adverse Events (TEAE).","timeFrame":"up to 5 years","effectByArm":[{"arm":"Fampridine-SR 10mg (Twice a Day)","deltaMin":264,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":32,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":["http://www.acorda.com/clinical.asp"]},"adverseEventsSummary":{"seriousAny":{"events":94,"n":269},"commonTop":["Urinary Tract Infection","Fall","Multiple Sclerosis Relapse","Arthralgia","Oedema Peripheral"]}}